gms | German Medical Science

10th Munich Vascular Conference

01.-03.12.2021, online

Sulodexide for superficial vein thrombosis treatment and secondary VTE prophylaxis

Meeting Abstract

10th Munich Vascular Conference. sine loco [digital], 01.-03.12.2021. Düsseldorf: German Medical Science GMS Publishing House; 2021. Doc16

doi: 10.3205/21mac16, urn:nbn:de:0183-21mac164

Veröffentlicht: 22. Dezember 2021

© 2021 Machusky et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe



Background: The outdated consideration about superficial vein thrombosis (SVT) as a benign and self-limiting condition, not requiring anticoagulant therapy has been completely changed on arrival of new data indicating a high risk of venous thromboembolism (VTE) in 3 months following the first episode of thrombophlebitis and persistence of this trend up to 5 years of observations [1]. Meanwhile, Sulodexide showed extremely high efficacy in VTE prophylaxis without increasing the rate of major bleeding in a SURVET study [2]. This drug possesses anti-inflammatory properties thus reducing glycocalyx dysfunction (plays an important role in the pathogenesis of SVT [3], [4]), making possible the reduction of tributary superficial vein thrombosis symptoms and reducing the risk of secondary VT. This is the hypothesis of this study.

Methods: 72 patients with clinical signs of SVT in the great saphenous vein GSV (61 patients) and small saphenous vein SSV (11 patients) system were identified. According to ultrasound data, trunks’ valves were incompetent, and thrombosis was limited by GSV or SSV tributaries in all patients. The average term of clinical thrombophlebitis manifestation was 6 ± 3.2 days. All patients had got conservative therapy, including nonsteroidal anti-inflammatory drugs, 2nd class compression stockings. 12 patients had got prophylactic doses of low molecular weight heparin at one week due to severe clinical symptoms. All patients administered 500 lipasemic units of Sulodexide twice daily for 3 months. The primary endpoint was the elongation of thrombosis to the saphenous veins’ trunks, as well VTE symptoms within 3 months according to clinical signs and ultrasound examination.

Results: In 76% of patients, recanalization of the tributaries was observed after one-month treatment. All patients noted significant clinical improvement after first week of treatment. Thrombosis elongation to saphenous trunks was found in 5 (7%) patients. The recurrence rate of VTE was 1.4% (recurrent episode of STV in 1 patient). There were no serious adverse events (bleeding or pulmonary embolism during treatment.

Conclusion: Sulodexide seems to be effective and safe in treatment of tributary superficial vein thrombosis, thus reducing the incidence of secondary VTE after the first episode of SVT. Further clinical investigations are needed to determine the effectiveness of sulodexide for superficial vein thrombosis treatment.


Cannegieter SC, Horváth-Puhó E, Schmidt M, Dekkers OM, Pedersen L, Vandenbroucke JP, Sørensen HT. Risk of venous and arterial thrombotic events in patients diagnosed with superficial vein thrombosis: a nationwide cohort study. Blood. 2015 Jan 8;125(2):229-35. DOI: 10.1182/blood-2014-06-577783 Externer Link
Andreozzi GM, Bignamini AA, Davì G, Palareti G, Matuška J, Holý M, Pawlaczyk-Gabriel K, Džupina A, Sokurenko GY, Didenko YP, Andrei LD, Lessiani G, Visonà A; SURVET Study Investigators. Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Circulation. 2015 Nov 17;132(20):1891-7. DOI: 10.1161/CIRCULATIONAHA.115.016930 Externer Link
Mannello F, Ligi D, Raffetto JD. Glycosaminoglycan sulodexide modulates inflammatory pathways in chronic venous disease. Int Angiol. 2014 Jun;33(3):236-42.
Falcinelli E, Cosmi B, Filippini M, Petito E, Legnani C, Cini M, Guglielmini G, Migliacci R, Palareti G, Gresele P. Endothelial activation in patients with superficial vein thrombosis (SVT) of the lower limbs. Thromb Res. 2017 Sep;157:20-22. DOI: 10.1016/j.thromres.2017.06.033 Externer Link